The global thrombosis market size is expected to reach US$ 47,000 Mn by 2026, In terms of revenue and expanding at a CAGR of 9.5% from 2019 to 2026. The increasing burden of obesity has also changed significantly in the last one decade, globally. Both developed and emerging markets are having significant issues in controlling the associated diseases. The growing consumption of alcohol and tobacco, with overweight and obesity, adds a high risk of developing significant high blood pressure on veins for a large period of life leading to several thrombosis related complications, thus driving this market. Other factors contributing to the growth of this market are increasing the burden of cardiovascular and trauma cases, with the increasing R&D expenditure in the field of hematological disorders.
The report analyzes and forecasts the thrombosis drugs market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of thrombosis drugs, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major thrombosis drugs companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of thrombosis drugs upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of thrombosis drugs and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global thrombosis drugs market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the thrombosis drugs market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of thrombosis drugs market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Companies Mentioned in Report
The report also profiles major players in the market and provides various attributes such as company overview, financial overview, drug class portfolios, business strategies, and recent developments. Major companies profiled in the thrombosis drugs market include GlaxoSmithKline plc, Baxter International Inc., Johnson & Johnson, Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, Bayer AG, Aspen Pharmacare Holdings Limited, Boehringer Ingelheim GmbH, and Pfizer, Inc.
The global thrombosis drugs market has been segmented as follows:
Thrombosis Drugs Market, by Drug Class
Thrombosis Drugs Market, by Indication
Thrombosis Drugs Market, by Distribution Channel
Thrombosis Drugs Market, by Geography
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2. Assumptions and Research Methodology
Chapter 3. Executive Summary : Global Thrombosis Drugs Market
Chapter 4. Market Overview
4.1. Introduction
4.1.1. Drug Class Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Pipeline Analysis – Thrombosis Drugs Market
4.4. Thrombosis Drugs Sales Analysis
4.5. Thrombosis Drugs Market Value Chain Analysis
4.6. Global Thrombosis Drugs Market Analysis and Forecasts, 2017–2026
4.6.1. Market Revenue Projection (US$ Mn)
4.6.2. Market Outlook
4.7. Key Trends
Chapter 5. Global Thrombosis Drugs Market Analysis and Forecasts, by Drug Class
5.1. Key Findings / Developments
5.2. Introduction & Definition
5.3. Market Value Forecast, by Drug Class, 2018–2026
5.3.1. Factor Xa Inhibitor
5.3.2. Low Molecular Weight Heparin
5.3.3. P2Y12 Platelet Inhibitor
5.3.4. Others
5.4. Market Attractiveness, by Drug Class
Chapter 6. Global Thrombosis Drugs Market Analysis and Forecasts, by Indication
6.1. Key Findings / Developments
6.2. Introduction & Definition
6.3. Market Value Forecast, by Indication, 2018–2026
6.3.1. Pulmonary Embolism
6.3.2. Atrial Fibrillation
6.3.3. Deep Vein Thrombosis
6.3.4. Others
6.4. Market Attractiveness, by Indication
Chapter 7. Global Thrombosis Drugs Market Analysis and Forecasts, by Distribution Channel
7.1. Key Findings / Developments
7.2. Introduction & Definition
7.3. Market Value Forecast, by Distribution Channel, 2018–2026
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Market Attractiveness, by Distribution Channel
Chapter 8. Global Thrombosis Drugs Market Analysis and Forecasts, by Geography/Region
8.1. Geographical Representation
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
Chapter 9. North America Thrombosis Drugs Analysis and Forecast
9.1. Market Value Forecast, by Country, 2018–2026
9.1.1. U.S.
9.1.2. Canada
9.2. Market Value Share Analysis, by Drug Class, 2018–2026
9.3. Market Value Forecast, by Drug Class, 2017–2026
9.3.1. Factor Xa Inhibitor
9.3.2. Low Molecular Weight Heparin
9.3.3. P2Y12 Platelet Inhibitor
9.3.4. Others
9.4. Market Value Share Analysis, by Indication, 2018–2026
9.5. Market Value Forecast, by Indication, 2017–2026
9.5.1. Pulmonary Embolism
9.5.2. Atrial Fibrillation
9.5.3. Deep Vein Thrombosis
9.5.4. Others
9.6. Market Value Share Analysis, by Distribution Channel, 2018–2026
9.7. Market Value Forecast, by Distribution Channel, 2017–2026
9.7.1. Hospital Pharmacies
9.7.2. Retail Pharmacies
9.7.3. Online Pharmacies
9.8. Market Attractiveness Analysis
9.8.1. By Country
9.8.2. By Drug Class
9.8.3. By Indication
9.8.4. By Distribution Channel
Chapter 10. Europe Thrombosis Drugs Market Analysis and Forecast
10.1. Market Value Forecast, by Country , 2018–2025
10.1.1. Germany
10.1.2. France
10.1.3. U.K.
10.1.4. Spain
10.1.5. Italy
10.1.6. Rest of Europe
10.2. Market Value Share Analysis, by Drug Class, 2018–2026
10.3. Market Value and Volume Forecast, by Drug Class, 2017–2026
10.3.1. Factor Xa Inhibitor
10.3.2. Low Molecular Weight Heparin
10.3.3. P2Y12 Platelet Inhibitor
10.3.4. Others
10.4. Market Value Share Analysis, by Indication, 2018–2026
10.5. Market Value Forecast, by Indication, 2017–2026
10.5.1. Pulmonary Embolism
10.5.2. Atrial Fibrillation
10.5.3. Deep Vein Thrombosis
10.5.4. Others
10.6. Market Value Share Analysis, by Distribution Channel, 2018–2026
10.7. Market Value Forecast, by Distribution Channel, 2017–2026
10.7.1. Hospital Pharmacies
10.7.2. Retail Pharmacies
10.7.3. Online Pharmacies
10.8. Market Attractiveness Analysis
10.8.1. By Country
10.8.2. By Drug Class
10.8.3. By Indication
10.8.4. By Distribution Channel
Chapter 11. Asia Pacific Thrombosis Drugs Market Analysis and Forecast
11.1. Market Value Forecast, by Country , 2018–2025
11.1.1. China
11.1.2. Japan
11.1.3. India
11.1.4. Australia & New Zealand
11.1.5. Rest of APAC
11.2. Market Value Share Analysis, by Drug Class, 2018–2026
11.3. Market Value and Volume Forecast, by Drug Class, 2017–2026
11.3.1. Factor Xa Inhibitor
11.3.2. Low Molecular Weight Heparin
11.3.3. P2Y12 Platelet Inhibitor
11.3.4. Others
11.4. Market Value Share Analysis, by Indication, 2018–2026
11.5. Market Value Forecast, by Indication, 2017–2026
11.5.1. Pulmonary Embolism
11.5.2. Atrial Fibrillation
11.5.3. Deep Vein Thrombosis
11.5.4. Others
11.6. Market Value Share Analysis, by Distribution Channel, 2018–2026
11.7. Market Value Forecast, by Distribution Channel, 2017–2026
11.7.1. Hospital Pharmacies
11.7.2. Retail Pharmacies
11.7.3. Online Pharmacies
11.8. Market Attractiveness Analysis
11.8.1. By Country
11.8.2. By Drug Class
11.8.3. By Indication
11.8.4. By Distribution Channel
Chapter 12. Latin America Thrombosis Drugs Market Analysis and Forecast
12.1. Market Value Forecast, by Country, 2018–2025
12.1.1. Brazil
12.1.2. Mexico
12.1.3. Rest of LATAM
12.2. Market Value Share Analysis, by Drug Class, 2018–2026
12.3. Market Value and Volume Forecast, by Drug Class, 2017–2026
12.3.1. Factor Xa Inhibitor
12.3.2. Low Molecular Weight Heparin
12.3.3. P2Y12 Platelet Inhibitor
12.3.4. Others
12.4. Market Value Share Analysis, by Indication, 2018–2026
12.5. Market Value Forecast, by Indication, 2017–2026
12.5.1. Pulmonary Embolism
12.5.2. Atrial Fibrillation
12.5.3. Deep Vein Thrombosis
12.5.4. Others
12.6. Market Value Share Analysis, by Distribution Channel, 2018–2026
12.7. Market Value Forecast, by Distribution Channel, 2017–2026
12.7.1. Hospital Pharmacies
12.7.2. Retail Pharmacies
12.7.3. Online Pharmacies
12.8. Market Attractiveness Analysis
12.8.1. By Country
12.8.2. By Drug Class
12.8.3. By Indication
12.8.4. By Distribution Channel
Chapter 13. Middle East & Africa Thrombosis Drugs Market Analysis and Forecast
13.1. Market Value Forecast, by Country, 2018–2025
13.1.1. GCC Countries
13.1.2. South Africa
13.1.3. Israel
13.1.4. Rest of Middle East & Africa
13.2. Market Value Share Analysis, by Drug Class, 2018–2026
13.3. Market Value and Volume Forecast, by Drug Class, 2017–2026
13.3.1. Factor Xa Inhibitor
13.3.2. Low Molecular Weight Heparin
13.3.3. P2Y12 Platelet Inhibitor
13.3.4. Others
13.4. Market Value Share Analysis, by Indication, 2018–2026
13.5. Market Value Forecast, by Indication, 2017–2026
13.5.1. Pulmonary Embolism
13.5.2. Atrial Fibrillation
13.5.3. Deep Vein Thrombosis
13.5.4. Others
13.6. Market Value Share Analysis, by Distribution Channel, 2018–2026
13.7. Market Value Forecast, by Distribution Channel, 2017–2026
13.7.1. Hospital Pharmacies
13.7.2. Retail Pharmacies
13.7.3. Online Pharmacies
13.8. Market Attractiveness Analysis
13.8.1. By Country
13.8.2. By Drug Class
13.8.3. By Indication
13.8.4. By Distribution Channel
Chapter 14. Competition Landscape
14.1. Competition Matrix
14.1.1. GlaxoSmithKline plc. F. Hoffmann-La Roche Ltd.
14.1.2. Baxter International, Inc.
14.2. Company Profiles
14.2.1. GlaxoSmithKline plc.
14.2.1.1. Company Details
14.2.1.2. Company Description
14.2.1.3. Business Overview
14.2.1.4. SWOT Analysis
14.2.1.5. Financial Analysis
14.2.1.6. Strategic Overview
14.2.2. Baxter International, Inc.
14.2.2.1. Company Details
14.2.2.2. Company Description
14.2.2.3. Business Overview
14.2.2.4. SWOT Analysis
14.2.2.5. Strategic Overview
14.2.3. Johnson & Johnson
14.2.3.1. Company Details
14.2.3.2. Company Description
14.2.3.3. Business Overview
14.2.3.4. SWOT Analysis
14.2.3.5. Strategic Overview
14.2.4. Bayer AG
14.2.4.1. Company Details
14.2.4.2. Company Description
14.2.4.3. Business Overview
14.2.4.4. SWOT Analysis
14.2.4.5. Strategic Overview
14.2.5. Sanofi
14.2.5.1. Company Details
14.2.5.2. Company Description
14.2.5.3. Business Overview
14.2.5.4. SWOT Analysis
14.2.5.5. Financial Analysis
14.2.5.6. Strategic Overview
14.2.6. Bristol-Myers Squibb Company
14.2.6.1. Company Details
14.2.6.2. Company Description
14.2.6.3. Business Overview
14.2.6.4. SWOT Analysis
14.2.6.5. Financial Analysis
14.2.6.6. Strategic Overview
14.2.7. AstraZeneca plc
14.2.7.1. Company Details
14.2.7.2. Company Description
14.2.7.3. Business Overview
14.2.7.4. SWOT Analysis
14.2.7.5. Financial Analysis
14.2.7.6. Strategic Overview
14.2.8. Pfizer, Inc.
14.2.8.1. Company Details
14.2.8.2. Company Description
14.2.8.3. Business Overview
14.2.8.4. SWOT Analysis
14.2.8.5. Financial Analysis
14.2.8.6. Strategic Overview
14.2.9. Boehringer Ingelheim GmbH
14.2.9.1. Company Details
14.2.9.2. Company Description
14.2.9.3. Business Overview
14.2.9.4. SWOT Analysis
14.2.9.5. Strategic Overview
14.2.10. Aspen Pharmacare Holdings Limited
14.2.10.1. Company Details
14.2.10.2. Company Description
14.2.10.3. Business Overview
14.2.10.4. SWOT Analysis
14.2.10.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers